Article Text

Download PDFPDF
Piling Pelion upon Ossa: surely we already have enough non-evidence based ways of treating acute asthma?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @bigcatdoc

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MLL: reports speakers fees or fees for expert consultation from Clement Clarke International, Teva, AstraZeneca, Chiesi, Respiri, Trudel Pharmaceuticals, Soar Beyond, Orion Pharmaceuticals, Napp Pharmaceuticals, National Services for Health Improvement (a company providing services for general practices, ie, nurse asthma reviews), Novartis Pharmaceuticals and GlaxoSmithKlein; grants from Consorcio Futuro in Richerce and non-financial support from Asthma and COPD (Joint) Lead for Whole Systems Integrated Care (WSIC) NorthWest London and the Global Initiative on Asthma (GINA) outside the submitted work. LF: reports grants from Asthma UK, and speakers fees or fees for expert consultation from Teva, AstraZeneca, Sanofi, Respiri, Novartis; all fees paid direct to her institution and outside the submitted work.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles

  • Atoms
    Nick Brown